Quantifying the Benefits of Genome-Driven Oncology. - PubMed - NCBI

Quantifying the Benefits of Genome-Driven Oncology. - PubMed - NCBI

Cancer Discov. 2017 Jun;7(6):552-554. doi: 10.1158/2159-8290.CD-17-0380.

Quantifying the Benefits of Genome-Driven Oncology.

Schram AM1, Hyman DM2,3.

Author information

Abstract

The excitement surrounding genomically selected cancer therapy has led many to question whether this treatment paradigm is living up to its initial promise. The MOSCATO study suggests that a genome-driven strategy for cancer therapy improves outcomes in a significant minority of patients who undergo molecular screening. Cancer Discov; 7(6); 552-4. ©2017 AACR.See related article by Massard et al., p. 586.

©2017 American Association for Cancer Research.

PMID:

 

28576841

 

DOI:

 

10.1158/2159-8290.CD-17-0380